Medicenna to Present Clinical and Preclinical Data at the 39th Annual Meeting of the Society for Immunotherapy of Cancer (SITC)
04 oct. 2024 09h07 HE
|
Medicenna Therapeutics Corp.
Updated clinical results to be presented from the ongoing Phase 1/2 ABILITY-1 study of MDNA11 in advanced or metastatic solid tumors Preclinical data on MDNA113, Medicenna's first-in-class, masked,...
Medicenna Announces Results of Annual Meeting of Shareholders
26 sept. 2024 17h00 HE
|
Medicenna Therapeutics Corp.
TORONTO and HOUSTON, Sept. 26, 2024 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. (“Medicenna” or the “Company”) (TSX: MDNA, OTCQB: MDNAF), a clinical-stage immunotherapy company focused on the...
Medicenna Presents Preclinical Results from its IL-2 Super-Antagonist and Anti-PD1-IL-2 BiSKIT Programs at The Promise of Interleukin-2 Therapy Conference
09 sept. 2024 07h32 HE
|
Medicenna Therapeutics Corp.
MDNA209 is a first-in-class “beta-enhanced” IL-2 Super-antagonist being developed for the potential treatment of autoimmune diseases, a disorder attributed to an imbalance of the immune system and...
Medicenna to Participate at the H.C. Wainwright 26th Annual Global Investment Conference
05 sept. 2024 07h00 HE
|
Medicenna Therapeutics Corp.
TORONTO and HOUSTON, Sept. 05, 2024 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. (“Medicenna” or the “Company”) (TSX: MDNA, OTCQB: MDNAF), a clinical-stage immunotherapy company...
Medicenna Announces Upcoming Presentations at The Promise of Interleukin-2 Therapy Conference
27 août 2024 07h00 HE
|
Medicenna Therapeutics Corp.
TORONTO and HOUSTON, Aug. 27, 2024 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. (“Medicenna” or the “Company”) (TSX: MDNA, OTCQB: MDNAF), a clinical-stage immunotherapy company focused...
Medicenna Strengthens Board of Directors with Appointment of Karim Lalji
15 août 2024 07h30 HE
|
Medicenna Therapeutics Corp.
TORONTO and HOUSTON, Aug. 15, 2024 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. (“Medicenna” or the “Company”) (TSX: MDNA, OTCQB: MDNAF), a clinical-stage immunotherapy company focused on the...
Medicenna Reports First Quarter Fiscal 2025 Financial Results and Announces First Complete Responder with MDNA11 Monotherapy
01 août 2024 07h00 HE
|
Medicenna Therapeutics Corp.
Patient with melanoma, having failed dual check-point inhibitor therapy, achieved a complete response following treatment with MDNA11 at week 52 with 100% regression of all target and non-target...
Medicenna Therapeutics Reports Fiscal Year 2024 Financial Results and Operational Highlights
27 juin 2024 08h18 HE
|
Medicenna Therapeutics Corp.
Increased cash balance to $37 million following a $20 million investment by RA Capital extending runway into mid-2026 MDNA11 continues to exhibit compelling deep and durable single agent activity and...
Medicenna Announces EMA Approval of its Clinical Trial Application to Expand its Phase 1/2 ABILITY-1 Study to Europe
26 juin 2024 07h47 HE
|
Medicenna Therapeutics Corp.
- ABILITY-1 study is currently enrolling patients for the treatment of advanced solid tumors with MDNA11, a novel long-acting IL-2 super-agonist, as a monotherapy or in combination with KEYTRUDA®, at...
Medicenna Reports Significant Survival Benefit in Patients with Recurrent Glioblastoma Following Treatment with Bizaxofusp When Compared to a Matched External Control Arm at the 2024 ASCO Annual Meeting
03 juin 2024 08h00 HE
|
Medicenna Therapeutics Corp.
Single treatment with bizaxofusp achieved significant survival benefit (mOS of 13.5 vs. 7.2 months, p=0.009) and reduced risk of death by almost half (hazard ratio: 0.54, 95% confidence interval:...